LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 6 of total 6

Search options

  1. Article ; Online: Connecting the dots: spots on the skin, weakness within.

    Freyer, Luisa / Hoppe, John Michael / Saleh, Inas / Brunner, Stefan / Spiro, Judith / Steffen, Julius / Pappa, Eleni

    Infection

    2024  

    Language English
    Publishing date 2024-03-13
    Publishing country Germany
    Document type Journal Article
    ZDB-ID 185104-4
    ISSN 1439-0973 ; 0300-8126 ; 0173-2129
    ISSN (online) 1439-0973
    ISSN 0300-8126 ; 0173-2129
    DOI 10.1007/s15010-024-02227-8
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 881: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (1.OG)
    ab Jg. 2022: Lesesaal (EG)
    Zs.MO 528: Show issues

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  2. Article ; Online: Periodic repolarization dynamics: Different methods for quantifying low-frequency oscillations of repolarization.

    Sams, Lauren E / Wörndl, Maximilian / Bachinger, Leonie / Villegas Sierra, Laura E / Mourouzis, Konstantinos / Naumann, Dominik / Freyer, Luisa / Rizas, Konstantinos D

    Journal of electrocardiology

    2023  Volume 82, Page(s) 11–18

    Abstract: Background: Periodic repolarization dynamics (PRD) is an electrocardiographic biomarker that quantifies low-frequency (LF) instabilities of repolarization. PRD is a strong predictor of mortality in patients with ischaemic and non-ischaemic ... ...

    Abstract Background: Periodic repolarization dynamics (PRD) is an electrocardiographic biomarker that quantifies low-frequency (LF) instabilities of repolarization. PRD is a strong predictor of mortality in patients with ischaemic and non-ischaemic cardiomyopathy. Until recently, two methods for calculating PRD have been proposed. The wavelet analysis has been widely tested and quantifies PRD in deg
    Method: The first step for quantifying PRD is to calculate the beat-to-beat change in the direction of repolarization, called dT°. PRD is subsequently quantified by means of either wavelet or PRSA-analysis. We simulated 1.000.000 dT°-signals. For each simulated signal we calculated PRD using the wavelet and PRSA-method. We calculated the ratio between PRD
    Results: The ratio between PRD
    Conclusion: This is the first analytical investigation of the different methods used to calculate PRD using simulated and clinical data. In this article we propose a novel algorithm for converting PRD
    MeSH term(s) Humans ; Electrocardiography ; Myocardial Infarction ; Heart Rate ; Signal Processing, Computer-Assisted
    Language English
    Publishing date 2023-11-19
    Publishing country United States
    Document type Journal Article
    ZDB-ID 410286-1
    ISSN 1532-8430 ; 0022-0736
    ISSN (online) 1532-8430
    ISSN 0022-0736
    DOI 10.1016/j.jelectrocard.2023.11.005
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 701: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (1.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  3. Book ; Online ; Thesis: The addition of the novel heparan sulfate (HS) mimetic PG545 to standard chemotherapy shows promising efficacy in the treatment of ovarian cancer in vitro and in vivo

    Freyer, Luisa [Verfasser] / Schmidmaier, Ralf [Akademischer Betreuer]

    2018  

    Author's details Luisa Freyer ; Betreuer: Ralf Schmidmaier
    Keywords Medizin, Gesundheit ; Medicine, Health
    Subject code sg610
    Language English
    Publisher Universitätsbibliothek der Ludwig-Maximilians-Universität
    Publishing place München
    Document type Book ; Online ; Thesis
    Database Digital theses on the web

    Full text online

    More links

    Kategorien

    Inter-library loan at ZB MED

    Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

  4. Article ; Online: Smartphone-based screening for atrial fibrillation: a pragmatic randomized clinical trial.

    Rizas, Konstantinos D / Freyer, Luisa / Sappler, Nikolay / von Stülpnagel, Lukas / Spielbichler, Peter / Krasniqi, Aresa / Schreinlechner, Michael / Wenner, Felix N / Theurl, Fabian / Behroz, Amira / Eiffener, Elodie / Klemm, Mathias P / Schneidewind, Annika / Zens, Martin / Dolejsi, Theresa / Mansmann, Ulrich / Massberg, Steffen / Bauer, Axel

    Nature medicine

    2022  Volume 28, Issue 9, Page(s) 1823–1830

    Abstract: Digital smart devices have the capability of detecting atrial fibrillation (AF), but the efficacy of this type of digital screening has not been directly compared to usual care for detection of treatment-relevant AF. In the eBRAVE-AF trial ( NCT04250220 ) ...

    Abstract Digital smart devices have the capability of detecting atrial fibrillation (AF), but the efficacy of this type of digital screening has not been directly compared to usual care for detection of treatment-relevant AF. In the eBRAVE-AF trial ( NCT04250220 ), we randomly assigned 5,551 policyholders of a German health insurance company who were free of AF at baseline (age 65 years (median; interquartile range (11) years, 31% females)) to digital screening (n = 2,860) or usual care (n = 2,691). In this siteless trial, for digital screening, participants used a certified app on their own smartphones to screen for irregularities in their pulse waves. Abnormal findings were evaluated by 14-day external electrocardiogram (ECG) loop recorders. The primary endpoint was newly diagnosed AF within 6 months treated with oral anti-coagulation by an independent physician not involved in the study. After 6 months, participants were invited to cross-over for a second study phase with reverse assignment for secondary analyses. The primary endpoint of the trial was met, as digital screening more than doubled the detection rate of treatment-relevant AF in both phases of the trial, with odds ratios of 2.12 (95% confidence interval (CI), 1.19-3.76; P = 0.010) and 2.75 (95% CI, 1.42-5.34; P = 0.003) in the first and second phases, respectively. This digital screening technology provides substantial benefits in detecting AF compared to usual care and has the potential for broad applicability due to its wide availability on ordinary smartphones. Future studies are needed to test whether digital screening for AF leads to better treatment outcomes.
    MeSH term(s) Atrial Fibrillation/diagnosis ; Atrial Fibrillation/drug therapy ; Child ; Delivery of Health Care ; Electrocardiography ; Female ; Humans ; Male ; Mass Screening ; Smartphone
    Language English
    Publishing date 2022-08-28
    Publishing country United States
    Document type Journal Article ; Randomized Controlled Trial
    ZDB-ID 1220066-9
    ISSN 1546-170X ; 1078-8956
    ISSN (online) 1546-170X
    ISSN 1078-8956
    DOI 10.1038/s41591-022-01979-w
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 4212: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (2.OG)
    ab Jg. 2022: Lesesaal (EG)
    Zs.MG 39: Show issues

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  5. Article ; Online: Rationale and design of a digital trial using smartphones to detect subclinical atrial fibrillation in a population at risk: The eHealth-based bavarian alternative detection of Atrial Fibrillation (eBRAVE-AF) trial.

    Freyer, Luisa / von Stülpnagel, Lukas / Spielbichler, Peter / Sappler, Nikolay / Wenner, Felix / Schreinlechner, Michael / Krasniqi, Aresa / Behroz, Amira / Eiffener, Elodie / Zens, Martin / Dolejsi, Theresa / Massberg, Steffen / Rizas, Konstantinos D / Bauer, Axel

    American heart journal

    2021  Volume 241, Page(s) 26–34

    Abstract: Current guidelines recommend opportunistic screening for subclinical atrial fibrillation (AF) taking advantage of e-health-based technologies. However, the efficacy of a fully scalable e-health-based strategy for AF detection in a head-to-head comparison ...

    Abstract Current guidelines recommend opportunistic screening for subclinical atrial fibrillation (AF) taking advantage of e-health-based technologies. However, the efficacy of a fully scalable e-health-based strategy for AF detection in a head-to-head comparison with routine symptom-based screening is unknown. eBRAVE-AF is an investigator-initiated, digital, prospective, randomized, siteless, open-label, cross-over study to evaluate an e-health-based strategy for detection of AF in a real-world setting. 67,488 policyholders of a large German health insurance company (Versicherungskammer Bayern, Germany) selected by age ≥ 50 years and a CHA
    MeSH term(s) Asymptomatic Diseases/epidemiology ; Atrial Fibrillation/complications ; Atrial Fibrillation/diagnosis ; Atrial Fibrillation/drug therapy ; Atrial Fibrillation/epidemiology ; Cross-Over Studies ; Female ; Germany/epidemiology ; Humans ; Insurance, Health/statistics & numerical data ; Male ; Middle Aged ; Mobile Applications ; Monitoring, Ambulatory/instrumentation ; Monitoring, Ambulatory/methods ; Randomized Controlled Trials as Topic/methods ; Smartphone ; Telemedicine/instrumentation ; Telemedicine/methods
    Language English
    Publishing date 2021-07-09
    Publishing country United States
    Document type Clinical Trial Protocol ; Journal Article
    ZDB-ID 80026-0
    ISSN 1097-6744 ; 0002-8703
    ISSN (online) 1097-6744
    ISSN 0002-8703
    DOI 10.1016/j.ahj.2021.06.008
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Ui IV Zs.15: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  6. Article ; Online: PG545 enhances anti-cancer activity of chemotherapy in ovarian models and increases surrogate biomarkers such as VEGF in preclinical and clinical plasma samples.

    Winterhoff, Boris / Freyer, Luisa / Hammond, Edward / Giri, Shailendra / Mondal, Susmita / Roy, Debarshi / Teoman, Attila / Mullany, Sally A / Hoffmann, Robert / von Bismarck, Antonia / Chien, Jeremy / Block, Matthew S / Millward, Michael / Bampton, Darryn / Dredge, Keith / Shridhar, Viji

    European journal of cancer (Oxford, England : 1990)

    2015  Volume 51, Issue 7, Page(s) 879–892

    Abstract: Background: Despite the utility of antiangiogenic drugs in ovarian cancer, efficacy remains limited due to resistance linked to alternate angiogenic pathways and metastasis. Therefore, we investigated PG545, an anti-angiogenic and anti-metastatic agent ... ...

    Abstract Background: Despite the utility of antiangiogenic drugs in ovarian cancer, efficacy remains limited due to resistance linked to alternate angiogenic pathways and metastasis. Therefore, we investigated PG545, an anti-angiogenic and anti-metastatic agent which is currently in Phase I clinical trials, using preclinical models of ovarian cancer.
    Methods: PG545's anti-cancer activity was investigated in vitro and in vivo as a single agent, and in combination with paclitaxel, cisplatin or carboplatin using various ovarian cancer cell lines and tumour models.
    Results: PG545, alone, or in combination with chemotherapeutics, inhibited proliferation of ovarian cancer cells, demonstrating synergy with paclitaxel in A2780 cells. PG545 inhibited growth factor-mediated cell migration and reduced HB-EGF-induced phosphorylation of ERK, AKT and EGFR in vitro and significantly reduced tumour burden which was enhanced when combined with paclitaxel in an A2780 model or carboplatin in a SKOV-3 model. Moreover, in the immunocompetent ID8 model, PG545 also significantly reduced ascites in vivo. In the A2780 maintenance model, PG545 initiated with, and following paclitaxel and cisplatin treatment, significantly improved overall survival. PG545 increased plasma VEGF levels (and other targets) in preclinical models and in a small cohort of advanced cancer patients which might represent a potential biomarker of response.
    Conclusion: Our results support clinical testing of PG545, particularly in combination with paclitaxel, as a novel therapeutic strategy for ovarian cancer.
    MeSH term(s) Animals ; Antineoplastic Combined Chemotherapy Protocols/therapeutic use ; Biomarkers, Tumor/blood ; Cisplatin/administration & dosage ; Drug Synergism ; Female ; Humans ; Mice ; Mice, Inbred C57BL ; Mice, SCID ; Neoplasms/blood ; Neoplasms/drug therapy ; Ovarian Neoplasms/blood ; Ovarian Neoplasms/drug therapy ; Ovarian Neoplasms/pathology ; Paclitaxel/administration & dosage ; Saponins/administration & dosage ; Saponins/pharmacology ; Tumor Cells, Cultured ; Up-Regulation/drug effects ; Vascular Endothelial Growth Factor A/blood ; Xenograft Model Antitumor Assays
    Chemical Substances Biomarkers, Tumor ; PG 545 ; Saponins ; VEGFA protein, human ; Vascular Endothelial Growth Factor A ; Paclitaxel (P88XT4IS4D) ; Cisplatin (Q20Q21Q62J)
    Language English
    Publishing date 2015-05
    Publishing country England
    Document type Clinical Trial, Phase I ; Journal Article ; Research Support, N.I.H., Extramural ; Research Support, Non-U.S. Gov't
    ZDB-ID 82061-1
    ISSN 1879-0852 ; 0277-5379 ; 0959-8049 ; 0964-1947
    ISSN (online) 1879-0852
    ISSN 0277-5379 ; 0959-8049 ; 0964-1947
    DOI 10.1016/j.ejca.2015.02.007
    Database MEDical Literature Analysis and Retrieval System OnLINE

    Full text online

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 456: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (1.OG)
    ab Jg. 2022: Lesesaal (EG)
    Zs.MO 583: Show issues

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

To top